API enterprises extend industrial chain and transform to preparations

With the continuous development of pharmaceutical industry, the development mode of API industry is also changing The previous business model of low added value and at the expense of environment is no longer suitable for the development of API enterprises Many raw material pharmaceutical companies have begun to shift from producing extensive low-end products to fine products, or to find new breakthrough directions At present, large API enterprises are gradually transforming into preparations, one is to digest their own APIs, the other is to increase profits One industry person said In this direction, in addition to the advantages of the brand itself, some API enterprises also have the advantages of human resources in drug research and development In addition, in recent years, China has also implemented some policies and financial support to encourage enterprises to develop preparation internationalization and provide industrial transformation and upgrading, and a large number of enterprises, such as Huahai, Haizheng and Jingxin pharmaceutical, have also benefited to varying degrees According to the data, Beijing New Pharmaceutical Co., Ltd has completed the project of four first generic drugs to be developed, and there are many varieties to be developed, such as atorvastatin and clopidogrel Dongyangguang Pharmaceutical Co., Ltd is also conducting the European and American distribution of preparation products At present, 7 products have passed the EU cGMP certification, and 3 products have passed the FDA certification It is true that for enterprises, the choice of transformation direction is the first consideration The transformation of API manufacturing enterprises is to extend the industrial chain along the direction of API products, that is to say, their own preparations are mainly their own APIs, thus forming a closed-loop transformation path with low transformation cost, and at the same time, the risk of this transformation path is small Of course, if API companies can develop, strongly imitate or acquire "heavyweight" products by themselves, or rebuild competitive disease product groups Take Haizheng for example Because of the joint venture with Pfizer, Haizheng has gained the transformation opportunity, built a new profit center, and successfully transformed from a raw material enterprise to a pharmaceutical enterprise Because of the marriage with Pfizer, it has gained the advantage of new drug research and development, forming a product group centered on haizhenghui At present, with the help of Haizheng, Pfizer has established a stable position in China's generic pharmaceutical market, Haizheng has obtained a strong new drug R & D capability with the help of Pfizer's transformation, and the cooperation between the two is successful But it needs to be clear that, while borrowing from each other, we should pay more attention to the improvement of our enterprises' R & D, distribution and operation capabilities The choice of transformation path is related to the actual needs of each enterprise, such as R & D innovation ability, resource allocation ability, etc Enterprises with strength can choose to expand the export of preparations, but for enterprises with relatively difficult export of preparations, it's also necessary to develop the domestic market first.